Implementation of a Pharmacist-Led Transitions of Care Program within a Primary Care Practice: A Two-Phase Pilot Study.
pilot study
primary care
readmissions
transitions of care
Journal
Pharmacy (Basel, Switzerland)
ISSN: 2226-4787
Titre abrégé: Pharmacy (Basel)
Pays: Switzerland
ID NLM: 101678532
Informations de publication
Date de publication:
04 Jan 2020
04 Jan 2020
Historique:
received:
21
11
2019
revised:
19
12
2019
accepted:
31
12
2019
entrez:
18
1
2020
pubmed:
18
1
2020
medline:
18
1
2020
Statut:
epublish
Résumé
Pharmacists in primary care settings have unique opportunities to address the causes of ineffective care transitions. The objective of this study is to describe the implementation of a multifaceted pharmacist transitions of care (TOC) intervention integrated into a primary care practice and evaluate the effectiveness of the program. This was a two-phase pilot study describing the development, testing, and evaluation of the TOC program. In Phase 1, the TOC intervention was implemented in a general patient population, while Phase 2 focused the intervention on high-risk patients. The two pilot phases were compared to each other (Phase 1 vs. Phase 2) and to a historical control group of patients who received usual care prior to the intervention (Phase 1 and Phase 2 vs. control). The study included 138 patients in the intervention group (Phase 1: 101 and Phase 2: 37) and 118 controls. At baseline, controls had a significantly lower LACE index, shorter length of stay, and a lower number of medications at discharge, indicating less medical complexity. A total of 344 recommendations were provided over both phases, approximately 80% of which were accepted. In adjusted models, there were no significant differences in 30-day all-cause readmissions between Phase 2 and controls (aOR 0.78; 95% CI 0.21-2.89;
Identifiants
pubmed: 31947920
pii: pharmacy8010004
doi: 10.3390/pharmacy8010004
pmc: PMC7151670
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : NCATS NIH HHS
ID : KL2 TR001413
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA113951
Pays : United States
Références
J Pharm Pract. 2018 Oct 21;:897190018806400
pubmed: 30343615
Br J Clin Pharmacol. 2010 Nov;70(5):749-55
pubmed: 21039769
J Am Pharm Assoc (2003). 2013 Jan-Feb;53(1):78-84
pubmed: 23636160
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
J Clin Pharm Ther. 2016 Apr;41(2):128-44
pubmed: 26913812
J Am Pharm Assoc (2003). 2019 Dec 19;:
pubmed: 31866384
Arch Intern Med. 2006 Mar 13;166(5):565-71
pubmed: 16534045
Am J Manag Care. 2017 Mar;23(3):170-176
pubmed: 28385023
J Manag Care Spec Pharm. 2015 Aug;21(8):614-36
pubmed: 26233535
BMJ Open. 2016 Jun 27;6(6):e011060
pubmed: 27354072
Circulation. 2015 May 19;131(20):1796-803
pubmed: 25986448
J Prim Care Community Health. 2014 Jan 1;5(1):14-8
pubmed: 24327590
Arch Intern Med. 2009 Nov 23;169(21):2003-10
pubmed: 19933963
JAMA Intern Med. 2016 Apr;176(4):496-502
pubmed: 26954698
Ann Pharmacother. 2002 Sep;36(9):1331-6
pubmed: 12196047
CMAJ. 2010 Apr 6;182(6):551-7
pubmed: 20194559
Arch Intern Med. 2005 Sep 12;165(16):1842-7
pubmed: 16157827
Ann Pharmacother. 2014 May 27;48(9):1120-1128
pubmed: 24867583
J Pharm Pract. 2018 Apr;31(2):175-182
pubmed: 28468524
J Patient Saf. 2013 Sep;9(3):150-3
pubmed: 23965837
Adm Policy Ment Health. 2011 Mar;38(2):65-76
pubmed: 20957426
Ann Intern Med. 2003 Feb 4;138(3):161-7
pubmed: 12558354
N C Med J. 2018 Jan-Feb;79(1):4-13
pubmed: 29439095
J Gen Intern Med. 2014 May;29(5):798-804
pubmed: 24687289
N Engl J Med. 2009 Apr 2;360(14):1418-28
pubmed: 19339721
Mayo Clin Proc Innov Qual Outcomes. 2018 Feb 01;2(1):4-9
pubmed: 30225426
JAMA. 2011 Oct 19;306(15):1688-98
pubmed: 22009101